Full Press Release Details
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024.
IDYA
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
Key Takeaway: IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
Price reaction · baseline $33.29 (2024-07-03 close) · hit after-hours · 6 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+2.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma